ARCHIVES

FDA Expands Nexavar Indication To Include Thyroid Cancer

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI To Move Todaro’s Lab to FCR; Cinnamyl Anthranilate Was Carciogenic In Bioassay

March 28, 1980

Also: NCCN Committee Reaffirms Clinical Guideline Covering Avastin for Breast Cancer Indication

July 22, 2011

Letter; ASSIST Prevents Cancer, Should Remain in NCI Portfolio

July 4, 1997

NTP Board Approves Concept For New Mutagenesis Assays

January 1, 1988

Top Officials Resign From San Antonio’s Institute for Drug Development.

January 26, 2007

DCT Moves Fast to Take Control Of Cooperative Groups, Get Multimodality Studies Under Way

October 3, 1975